In Re: National Prescription Opiate Litigation

Track this case

Case Number:

1:17-md-02804

See also:

Court:

Ohio Northern

Nature of Suit:

P.I.: Other

Multi Party Litigation:

Class Action, Multi-district Litigation

Judge:

Dan Aaron Polster (MDL 28

Firms

Companies

Government Agencies

Sectors & Industries:

  1. January 02, 2023

    Health Care & Life Sciences Litigation To Watch In 2023

    Before the New Year's Eve confetti has even been swept up, lawyers specializing in health care and life sciences already have enough litigation to keep them busy for much of 2023, which is kicking off with federal courts eyeing suits that carry sweeping significance for administrative law, the False Claims Act, drug approvals, the opioid crisis and abortion rights.

  2. December 13, 2022

    6th Circ. Rejects Challenge To Opioid MDL Fee Order

    A Sixth Circuit panel on Tuesday threw out challenges to a common benefit order in the sprawling opioid multidistrict litigation that sets aside a portion of future settlements to pay plaintiffs' counsel, saying the challengers don't have standing to undo the order through an appeal.

  3. December 12, 2022

    Walgreens And CVS Finalize $10.7B Opioid Fallout Deal

    Walgreens and CVS have nailed down the final details of their $10.7 billion deal with 18 states to end claims that they contributed to the national opioid crisis, according to statements Monday from multiple state attorneys general.

  4. December 01, 2022

    Top Opioid Target Kroger Inks $85M Deal, With $25M For Attys

    Supermarket giant Kroger is paying $85 million, including $25 million for plaintiff lawyers, to end opioid crisis lawsuits in New Mexico, according to settlement papers released Thursday, a relatively sizable sum that underscores the company's new status as a top target in nationwide opioid litigation. 

  5. November 23, 2022

    5 Years In, Opioid Attys Talk Historic Saga's Progress & Future

    Sprawling opioid litigation has unearthed pharmaceutical industry failures, altered attitudes about addiction and secured billions of dollars that are raising hopes that a bleak drug crisis in U.S. communities will eventually yield to brighter days, plaintiffs counsel told Law360 in a conversation about the five-year legal saga's progress — and its uncertain path forward.

  6. November 15, 2022

    Walmart Confirms $3B Deal Over Pharmacies' Opioid Sales

    Walmart officially revealed a $3.1 billion offer Tuesday aimed at ending thousands of lawsuits accusing its nationwide pharmacy network of fueling America's deadly crisis of opioid abuse, echoing similar settlements involving CVS Pharmacy and Walgreens.

  7. November 14, 2022

    6th Circ. Allows Opioid Judge's 'Unusual' Bellwether Approach

    An Ohio federal judge's policy of permitting local governments to overhaul bellwether complaints in multidistrict opioid litigation without facing a firm cutoff date is "unconventional" and "unusual" but not unacceptable, the Sixth Circuit ruled, rebuffing a large pharmacy chain's challenge.

  8. November 09, 2022

    Walgreens Faces $10B Opioid Trial Threat Despite $5B Deal

    New Mexico and Walgreens have submitted written closing arguments in the Land of Enchantment's opioid trial, and the state said it wants nearly $10 billion in damages — twice as much as Walgreens offered last week to settle opioid litigation across the entire country.

  9. November 04, 2022

    SF-Walgreens Opioid Trial Called Off Amid Settlement Talks

    Just days after Walgreens announced its $5 billion tentative settlement of nationwide opioid litigation, a California federal judge called off Monday's remedies trial in connection with an August decision that found the pharmacy giant liable for San Francisco's struggles with rampant opioid abuse.

  10. November 02, 2022

    After Pharmacy Deals, New Opioid Sellers In Legal 'Bull's-Eye'

    Multibillion-dollar settlements with top pharmacy retailers will shift a historic barrage of opioid litigation away from the last of its early targets and toward groups of pharmaceutical sellers and advisers whose business practices and legal defenses have received little attention, according to plaintiffs counsel and court records.